Trials / Unknown
UnknownNCT06344715
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
A Phase 1, Multi-center, Open-label, Dose-escalating Study to Evaluate the Safety and Tolerability of Triple Combination Regimen of SL-T10, GX-I7 and Pembrolizumab in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- Sponsor
- SL VAXiGEN · Industry
- Sex
- Male
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of SL-T10 and GX-I7 or SL-T10, GX-I7 and pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
Detailed description
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of SL-T10, GX-I7, and pembrolizumab in combination in patients with metastatic castration-resistant prostate cancer (mCRPC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SL-T10 | A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants |
| BIOLOGICAL | GX-I7 | A T-cell growth factor |
| BIOLOGICAL | Pembrolizumab | An immune check point inhibitor |
Timeline
- Start date
- 2022-10-17
- Primary completion
- 2024-10-31
- Completion
- 2024-10-31
- First posted
- 2024-04-03
- Last updated
- 2024-04-03
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06344715. Inclusion in this directory is not an endorsement.